References
- Ben-David MA, Elkayam R, Gelernter I, Pfeffer RM. 2016. Melatonin for prevention of breast radiation dermatitis: a phase II, prospective, double-blind randomized trial. Isr Med Assoc J. 18(3–4):188–192.
- Brzezinski A. 1997. Melatonin in humans. N Engl J Med. 336(3):186–195. https://doi.org/10.1056/NEJM199701163360306.
- Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. 1989. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 28(2):193–213. https://doi.org/10.1016/0165-1781(89)90047-4.
- Carpenter JS, Andrykowski MA. 1998. Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res. 45(1):5–13. https://doi.org/10.1016/S0022-3999(97)00298-5.
- Chen WY, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker LM, Schernhammer ES. 2014. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res Treat. 145(2):381–388. https://doi.org/10.1007/s10549-014-2944-4.
- Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. 2011. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the research and treatment of cancer quality of life questionnaire core 30. J Clin Oncol. 29(1):89–96. https://doi.org/10.1200/JCO.2010.28.0107.
- Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, Jennings NB, Scott S, Vence L, Wei Q. 2012. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One. 7(8):e42324. https://doi.org/10.1371/journal.pone.0042324. Epub 2012/08/08.
- Collins KP, Geller DA, Antoni M, Donnell DM, Tsung A, Marsh JW, Krane A, Antoni M, Marsh JW, Burke LE. 2017. Sleep duration is associated with survival in advanced cancer patients. Sleep Med. 32:208–212. https://doi.org/10.1016/j.sleep.2016.06.041.
- De Leon CF, Grady KL, Eaton C, Rucker-Whitaker C, Janssen I, Calvin J, Powell LH. 2009. Quality of life in a diverse population of patients with heart failure: baseline findings from the heart failure adherence and retention trial (HART). J Cardiopulm Rehabil Prev. 29(3):171–178. https://doi.org/10.1097/HCR.0b013e31819a0266.
- Del FE, Dev R, Hui D, Palmer L, Bruera E. 2013. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol. 31(10):1271–1276. https://doi.org/10.1200/JCO.2012.43.6766.
- Du-Quiton J, Wood PA, Burch JB, Grutsch JF, Gupta D, Tyer K, Lis CG, Levin RD, Quiton DF, Reynolds JL, et al. 2010. Actigraphic assessment of daily sleep-activity pattern abnormalities reflects self-assessed depression and anxiety in outpatients with advanced non-small cell lung cancer. Psychooncology. 19(2):180–189. https://doi.org/10.1002/pon.1539.
- Ferrans CE. 2007. Differences in what quality-of-life instruments measure. J Natl Cancer Inst Monogr. (37):22–26. https://doi.org/10.1093/jncimonographs/lgm008.
- Grutsch JF, Ferrans C, Wood PA, Du-Quiton J, Quiton DF, Reynolds JL, Ansell CM, Oh EY, Daehler MA, Levin RD. 2011a. The association of quality of life with potentially remediable disruptions of circadian sleep/activity rhythms in patients with advanced lung cancer. BMC Cancer. 11(1):11–193. https://doi.org/10.1186/1471-2407-11-193.
- Grutsch JF, Wood PA, Du-Quiton J, Reynolds JL, Lis CG, Levin RD, Ann Daehler M, Gupta D, Quiton DF, Hrushesky WJ. 2011b. Validation of actigraphy to assess circadian organization and sleep quality in patients with advanced lung cancer. J Circadian Rhythms. 9(0):4–9. https://doi.org/10.1186/1740-3391-9-4.
- Gupta D, Grutsch JF, Lis CG. 2008. Comparison of two quality of life instruments for cancer patients: the ferrans and powers quality of life index and the European Organisation for the research and treatment of cancer quality of life questionnaire C30. J Soc Integr Oncol. 6(1):13–18.
- Hansen MV, Andersen LT, Madsen MT, Hageman I, Rasmussen LS, Bokmand S, Rosenberg J, Gögenur I. 2014. Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: a randomized, double-blind, placebo-controlled trial. Breast Cancer Res Treat. 145(3):683–695. https://doi.org/10.1007/s10549-014-2962-2.
- Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, Giacchetti S, Coudert B, Iacobelli S, Genet D, et al. 2009. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 69(11):4700–4707. https://doi.org/10.1158/0008-5472.CAN-08-4747.
- Innominato PF, Komarzynski S, Palesh OG, Dallmann R, Bjarnason GA, Giacchetti S, Ulusakarya A, Bouchahda M, Haydar M, Ballesta A, et al. 2018. Circadian rest-activity rhythm as an objective biomarker of patient-reported outcomes in patients with advanced cancer. Cancer Med. 7(9):4396–4405. https://doi.org/10.1002/cam4.1711.
- Innominato PF, Roche VP, Palesh OG, Ulusakarya A, Spiegel D, Lévi FA. 2014. The circadian timing system in clinical oncology. Ann Med. 46(4):191–207. https://doi.org/10.3109/07853890.2014.916990.
- Kurdi MS, Muthukalai SP. 2016. The efficacy of oral melatonin in improving sleep in cancer patients with insomnia: a randomized double-blind placebo-controlled study. Indian J Palliat Care. 22(3):295–300. https://doi.org/10.4103/0973-1075.185039.
- Lévi F, Dugué PA, Innominato P, Karaboué A, Dispersyn G, Parganiha A, Giacchetti S, Moreau T, Focan C, Waterhouse J. 2014. Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival. Chronobiol Int. 31(8):891–900. https://doi.org/10.3109/07420528.2014.924523.
- Levin RD, Daehler MA, Grutsch JF, Quiton J, Lis CG, Peterson C, Gupta D, Watson K, Layer D, Huff-Adams S. 2005. Circadian function in patients with advanced non-small-cell lung cancer. Br J Cancer. 93(11):1202–1208. https://doi.org/10.1038/sj.bjc.6602859.
- Lissoni P, Barni S, Ardizzoia A, Paolorossi F, Crispino S, Tancini G, Tisi E, Archili C, De Toma D, Pipino G. 1992. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin. Oncology. 49(5):336–339. https://doi.org/10.1159/000227068.
- Lissoni P, Barni S, MandalA M, Ardizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F, Tancini G. 1999. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer. 35(12):1688–1692. https://doi.org/10.1016/S0959-8049(99)00159-8.
- Lissoni P, Paolorossi F, Tancini G, Barni S, Ardizzoia A, Brivio F, Zubelewicz B, Chatikhine V. 1996. Is there a role for melatonin in the treatment of neoplastic cachexia?. Eur J Cancer. 32A(8):1340–1343. https://doi.org/10.1016/0959-8049(96)00136-0.
- Marcheva B, Ramsey KM, Buhr ED, Kobayashi Y, Su H, Ko CH, Ivanova G, Omura C, Mo S, Martha H, et al. 2010. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature. 466(7306):627–631. https://doi.org/10.1038/nature09253.
- Mehnert A, Hartung TJ, Friedrich M, Vehling S, Brähler E, Härter M, Keller M, Schulz H, Wegscheider K, Weis J. 2018. One in two cancer patients is significantly distressed: prevalence and indicators of distress. Psychooncology. 27(1):75–82. https://doi.org/10.1002/pon.4464.
- Osoba D, Rodrigues G, Myles J, Zee B, Pater J. 1998. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 16(1):139–144. https://doi.org/10.1200/JCO.1998.16.1.139.
- Palesh O, Aldridge-Gerry A, Zeitzer JM, Koopman C, Neri E, Giese-Davis J, Jo B, Kraemer H, Nouriani B, Spiegel D. 2014. Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep. 37(5):837–842. https://doi.org/10.5665/sleep.3642.
- Rasmussen CR, Olsen MK, Johnsen AT, Petersen MA, Lindholm H, Andersen L, Villadsen B, Groenvold M, Pedersen L. 2015. Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: a double-blind placebo-controlled crossover trial. Cancer. 121(20):3727–3736. https://doi.org/10.1002/cncr.29563.
- Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ, Mills E. 2012. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther. 11(4):293–303. https://doi.org/10.1177/1534735411425484.
- Sloan JA, Frost MH, Berzon R, Dueck A, Guyatt G, Moinpour C, Sprangers M, Ferrans C, Cella D, Clinical Significance Consensus Meeting Group. 2006. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer. 14(10):988–998. https://doi.org/10.1007/s00520-006-0085-y.
- Sookprasert A, Johns NP, Phunmanee A, Pongthai P, Cheawchanwattana A, Johns J, Konsil J, Plaimee P, Porasuphatana S, Jitpimolmard S. 2014. Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial. Anticancer Res. 34(12):7327–7337.
- Sulli G, Lam MTY, Panda S. 2019. Interplay between circadian clock and cancer: new frontiers for cancer treatment. Trends Cancer. 5(8):475–494. https://doi.org/10.1016/j.trecan.2019.07.002.
- Talib WH. 2018. Melatonin and cancer hallmarks. Molecules. 23(3):518. https://doi.org/10.3390/molecules23030518.
- Wang YM, Jin BZ, Ai F, Duan CH, Lu YZ, Dong TF, Qing-lin Fu QL. 2012. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol. 9(5):1213–1220. https://doi.org/10.1007/s00280-012-1828-8.
- Zhao D, Yu Y, Shen Y, Liu Q, Zhao Z, Sharma R, Reiter RJ. 2019. Melatonin synthesis and function: evolutionary history in animals and plants. Front Endocrinol (Lausanne). 10:249. https://doi.org/10.3389/fendo.2019.00249.